EU/3/16/1664

About

On 30 May 2016, orphan designation (EU/3/16/1664) was granted by the European Commission to Alan Boyd Consultants Ltd, United Kingdom, for polyethylene glycol-modified human recombinant truncated cystathionine beta-synthase for the treatment of homocystinuria.

The sponsorship was transferred to Boyd Consultants Limited, Ireland, in March 2019.

Key facts

Active substance
Polyethylene glycol-modified human recombinant truncated cystathionine beta-synthase
Disease / condition
Treatment of homocystinuria
Date of first decision
30/05/2016
Outcome
Positive
EU designation number
EU/3/16/1664

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Boyd Consultants Limited
Dublin City University
DCU Invent
Glasnevin
Dublin 9
Ireland
Tel. +44 1270 270010
E-mail: regulatory@boydconsultants.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating